Barclays PLC raised its stake in Definitive Healthcare Corp. (NASDAQ:DH – Free Report) by 318.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,916 shares of the company’s stock after buying an additional 62,354 shares during the period. Barclays PLC owned 0.07% of Definitive Healthcare worth $366,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Point72 DIFC Ltd increased its stake in shares of Definitive Healthcare by 759.9% in the third quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock valued at $42,000 after buying an additional 8,215 shares during the period. Intech Investment Management LLC bought a new stake in Definitive Healthcare in the third quarter valued at approximately $55,000. Sanctuary Advisors LLC acquired a new stake in Definitive Healthcare during the 2nd quarter valued at approximately $85,000. Bleakley Financial Group LLC bought a new position in Definitive Healthcare during the 3rd quarter worth approximately $74,000. Finally, Glenmede Trust Co. NA lifted its position in shares of Definitive Healthcare by 41.1% in the 3rd quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock worth $82,000 after purchasing an additional 5,362 shares during the period. Institutional investors own 98.67% of the company’s stock.
Definitive Healthcare Stock Down 0.3 %
NASDAQ:DH opened at $3.94 on Monday. The firm has a 50-day simple moving average of $4.35 and a two-hundred day simple moving average of $4.48. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare Corp. has a fifty-two week low of $3.19 and a fifty-two week high of $10.62. The firm has a market cap of $455.15 million, a P/E ratio of -1.27, a P/E/G ratio of 3.26 and a beta of 1.41.
Insiders Place Their Bets
Wall Street Analysts Forecast Growth
DH has been the subject of a number of recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a report on Thursday. Barclays reiterated an “underweight” rating and set a $4.00 price target on shares of Definitive Healthcare in a report on Monday, January 13th. Finally, Stephens initiated coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.72.
Read Our Latest Report on Definitive Healthcare
Definitive Healthcare Company Profile
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Featured Articles
- Five stocks we like better than Definitive Healthcare
- Golden Cross Stocks: Pattern, Examples and Charts
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Oilfield Leader SLB: An AI Name You Need to Know
- EV Stocks and How to Profit from Them
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Want to see what other hedge funds are holding DH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definitive Healthcare Corp. (NASDAQ:DH – Free Report).
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.